Angiogenesis as a therapeutic target
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As compared to the traditional transwell method, the monolayer design also has the added advantage of easily generating shear stress.”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“This monolayer approach is very effective in applications where cylindrical vessel geometry of blood vessels is not very essential to the study, such as in the testing of drugs which prevent cancer cell migration because this method is high throughput and simple to fabricate [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
In the citing paper
“Shear stress helps cells arrange themselves to establish the barrier function [106].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [106]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“This followed from a phase III study showing a survival benefi”
BackgroundSelf-citationTumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundSelf-citationIsolation of Putative Progenitor Endothelial Cells for Angiogenesis
Asahara, T., Murohara, T., Sullivan, A., Silver, M., van der Zee, R., Li, T., Witzenbichler, B., Schatteman, G., & Isner, J. M. (1997) · Science · doi:10.1126/science.275.5302.964 · Cited by 8,725 · cited 1×
“reported the isolation of putative EPC from human peripheral blood, on the basis of cell-surface expression of CD34 and other endothelial marker”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“An alternative hypothesis has been proposed by Jai”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“Several fragments of larger proteins have been described as endogenous inhibitors of angiogenesis including endostati”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“So far, VEGF-A and its receptors are the best-characterized signalling pathway in developmental angiogenesi”
BackgroundVascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Self-citation
Research works printed but not linked: 1
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
Cited by
Items 501–600 of 1,007
Pyun, B., Choi, S., Lee, Y., Kim, T., Min, J., Kim, Y., Kim, B.-D., Kim, J.-H., Kim, T., Kim, Y.-M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2799 · Cited by 85
The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4
Su, M., Huang, J., Liu, S., Xiao, Y., Qin, X., Liu, J., Pi, C., Luo, T., Li, J., Chen, X., et al. (2016) · Scientific Reports · doi:10.1038/srep28139 · Cited by 89
Targeted therapies for thyroid tumors
Sherman, S. I. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.165 · Cited by 86
“19 Of the identified proangiogenic factors, vascular endothelial growth factor (VEGF) is key, binding to two receptor tyrosine kinases, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1sKDR), that also trigger MAPK signaling”
BackgroundBioconjugated gold nanoparticles accelerate the growth of new blood vessels through redox signaling
Nethi, S. K., Mukherjee, S., Veeriah, V., Barui, A. K., Chatterjee, S., & Patra, C. R. (2014) · Chemical Communications · doi:10.1039/c4cc06996j · Cited by 84
Zhang, B., Abreu, J. G., Zhou, K., Chen, Y., Hu, Y., Zhou, T., He, X., & Ma, J.-X. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906764107 · Cited by 85
“However, a number of natural antiangiogenic factors or angiogenic inhibitors have been identified (18).”
BackgroundLi, F., Zeng, H., & Ying, K. (2010) · Medical Oncology · doi:10.1007/s12032-010-9646-5 · Cited by 92
“Recently, several studies suggest the role of CSCs in angiogenesis in lung cancer [18, 19].”
BackgroundSuppression of tumor angiogenesis by targeting the protein neddylation pathway
Yao, W.-T., Wu, J.-F., Yu, G.-Y., Wang, R., Wang, K., Li, L.-H., Chen, P., Jiang, Y.-N., He, C., Lee, H. W., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.21 · Cited by 84
Singh, A., Bandi, M. L., Raje, N. S., Richardson, P. G. G., Palladino, M. A., Chauhan, D., & Anderson, K. C. (2011) · Blood · doi:10.1182/blood-2010-12-323857 · Cited by 92
Angiogenesis and Cancer Prevention: A Vision
Noonan, D. M., Benelli, R., & Albini, A. (2007) · Springer eBooks · doi:10.1007/978-3-540-37696-5_19 · Cited by 96
“Angiogenesis inhibition is now a clinical reality, the commercially available anti-VEGF antibody Avastin, or bevacizumab, significantly improves survival when combined with standard chemotherapy approaches (Ferrara and Kerbel 2005).”
BackgroundPredictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review)
Velegrakis, A., Kouvidi, E., Fragkiadaki, P., & Sifakis, S. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5292 · Cited by 88
Angiogenesis and antiangiogenic agents in cervical cancer
Tomao, F., Tomao, F., Rossi, L., Zaccarelli, E., Caruso, D., Zoratto, F., Panici, P. B., & Papa, A. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s68286 · Cited by 83
A role for planar cell polarity signaling in angiogenesis
Cirone, P., Lin, S., Griesbach, H. L., Zhang, Y., Slusarski, D. C., & Crews, C. M. (2008) · Angiogenesis · doi:10.1007/s10456-008-9116-2 · Cited by 96
“Given that pathological angiogenesis occurs in several diseases including diabetic retinopathy, age-related macular degeneration [71] and most notably in cancer [72, 73 ], anti-angiogenic therapeutic strategies are very attractive [74].”
Montel, V., Gaultier, A., Lester, R. D., Campana, W. M., & Gonias, S. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0683 · Cited by 82
“Development of novel agents that counteract angiogenesis has become a major focus for cancer therapeutics design (19, 20).”
BackgroundThe challenge of intratumour heterogeneity in precision medicine
Seoane, J., & Mattos‐Arruda, L. D. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12240 · Cited by 92
New Strategies in Advanced Cervical Cancer: From Angiogenesis Blockade to Immunotherapy
Tewari, K. S., & Monk, B. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1099 · Cited by 90
Huang, Q., Stalnecker, C., Zhang, C., McDermott, L. A., Iyer, P., O’Neill, J., Reimer, S., Cerione, R. A., & Katt, W. P. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.810101 · Cited by 84
“mitochondrial enzyme glutaminase; GLS2, liver glutaminase; VEGF, vascular endothelial growth factor; PDB, Protein Data Bank; r.m.s., root mean square. croARTICLE J. Biol.”
BackgroundXu, Y., Yang, Q., Liu, T., Li, K., Liu, Y., Zhu, C., Zhang, Z., Li, L., Zhang, C., Xie, M., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.054 · Cited by 87
Sanz, L., Santos-Valle, P., Alonso-Camino, V., Salas, C., Serrano, A., Vicario, J. L., Cuesta, Á. M., Compte, M., Sánchez‐Martín, D., & Álvarez‐Vallina, L. (2008) · Microvascular Research · doi:10.1016/j.mvr.2007.11.007 · Cited by 86
Kluza, E., Jacobs, I., Hectors, S. J. C. G., Mayo, K. H., Griffioen, A. W., Strijkers, G. J., & Nicolay, K. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.032 · Cited by 82
Thejass, P., & Kuttan, G. (2006) · Nitric Oxide · doi:10.1016/j.niox.2006.09.006 · Cited by 82
Yu, S.-H., Tang, D.-W., Hsieh, H., Wu, W.-S., Lin, B.-X., Chuang, E., Sung, H., & Mi, F. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.04.009 · Cited by 86
Bradshaw, M., Mansfield, A. S., & Peikert, T. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0315-7 · Cited by 89
“These include several tyrosine kinase inhibitors [71] and bevacizumab, a recombinant hu-”
BackgroundBhat, T. A., Nambiar, D. K., Tailor, D., Pal, A., Agarwal, R., & Singh, R. P. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0209 · Cited by 82
“Angiogenesis is the formation of new blood vessels and capillaries either de novo or from the preexisting ones, and is an important target in the treatment and management of solid tumors (1).”
BackgroundMarchioli, G., Luca, A. D., de Koning, E. J. P., Engelse, M. A., van Blitterswijk, C., Karperien, M., van Apeldoorn, A. A., & Moroni, L. (2016) · Advanced Healthcare Materials · doi:10.1002/adhm.201600058 · Cited by 92
Plants and their active compounds: natural molecules to target angiogenesis
Lǚ, K., Bhat, M., & Basu, S. (2016) · Angiogenesis · doi:10.1007/s10456-016-9512-y · Cited by 82
“Treatments targeting angiogenesis are effective for many diseases [5, 7, 10].”
BackgroundTriterpenes in cancer: significance and their influence
Gill, B. S., Kumar, S., & Navgeet (2016) · Molecular Biology Reports · doi:10.1007/s11033-016-4032-9 · Cited by 89
Eruslanov, E. B., Kaliberov, S. A., Daurkin, I., Kaliberova, L. N., Buchsbaum, D. J., Vieweg, J., & Kusmartsev, S. A. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802358 · Cited by 86
Binet, F., Mawambo, G., Sitaras, N., Tetreault, N., Lapalme, E., Favret, S., Cerani, A., Leboeuf, D., Tremblay, S., Rezende, F., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.003 · Cited by 80
“…be considered counterintuitive given the uncontestable involvement of VEGF in the pathogenesis of ocular neovascular disease (Aiello et al., 1995; Caldwell et al., 2003; Ferrara and Kerbel, 2005) and the currently employed antiangiogenic strategies for proliferative ocular disease (Stewart, 2012).”
BackgroundTechniques and assays for the study of angiogenesis
Irvin, M., Zijlstra, A., Wikswo, J. P., & Pozzi, A. (2014) · Experimental Biology and Medicine · doi:10.1177/1535370214529386 · Cited by 91
Osawa, T., Muramatsu, M., Wang, F., Tsuchida, R., Kodama, T., Minami, T., & Shibuya, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108462109 · Cited by 81
“Angiogenesis is regulated by multiple proangiogenic and antiangiogenic factors (1, 2).”
BackgroundTumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA
Liu, X., Wang, W., Samarsky, D., Liu, L., Xu, Q., Zhang, W., Zhu, G., Wu, P., Zuo, X., Deng, H., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku831 · Cited by 80
The involvement of lncRNAs in the development and progression of pancreatic cancer
Li, D., He, J., Qian, X., Peng, X., Xiao-dong, W., Li, Z., Jian-jun, Q., & Yao, J. J. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1385682 · Cited by 81
“Tumor neovascularization is a another critical tumor-supportive element for the stroma, where tumor cells release proangiogenic signals to recruit endothelial cells to form the neovasculature, thereby obtaining nutrients and oxygen or evacuating metabolic wastes during tumor growth and metastasis.(105,106) lncRNAs hav…”
BackgroundTumor angiogenesis and anti-angiogenic therapies
Shahneh, F. Z., Baradaran, B., Zamani, F., & Aghebati-Maleki, L. (2013) · Human Antibodies · doi:10.3233/hab-130267 · Cited by 80
“Anti-angiogenic compounds in use or in development for the treatment of cancer, inhibit VEGFR, PDGFR, KIT, colony-stimulating factor 1 receptor (CSF-1R), FMS-like tyrosine kinase 3 receptor (FLT3), RAF kinase and glial cell line-derived neurotrophic factor (RET), expressed by tumor cells [40,43].”
Ponesakki, G., Matsubara, K., Sugawara, T., & Hirata, T. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1651-5 · Cited by 84
“Most current angiogenesis inhibitors including antibodies of angiogenic growth factors and antagonists of specific receptors, have produced remarkable anti-tumor effects [13, 14].”
BackgroundGuma, M., Rius, J., Duong-Polk, K. X., Haddad, G. G., Lindsey, J. D., & Karin, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902659106 · Cited by 80
“Because this model is a well-characterized VEGF-dependent model (7, 14, 15) and suppression of VEGF expression or activity inhibits neovascularization in several diseases (3, 4), we examined whether the absence of JNK1 reduces VEGF expression.”
MethodGenetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis
Pisanti, S., Picardi, P., Prota, L., Proto, M., Laezza, C., McGuire, P. G., Morbidelli, L., Gazzerro, P., Ziche, M., Das, A., et al. (2011) · Blood · doi:10.1182/blood-2010-09-307355 · Cited by 95
Rgd-Mediated Delivery of Small-Molecule Drugs
Katsamakas, S., Chatzisideri, T., Thysiadis, S., & Sarli, V. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0008 · Cited by 86
The development and use of vascular targeted therapy in ovarian cancer
Chase, D. M., Chaplin, D. J., & Monk, B. J. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.01.031 · Cited by 85
The case for oxygen-ozonetherapy
Bocci, V. A. (2007) · British Journal of Biomedical Science · doi:10.1080/09674845.2007.11732755 · Cited by 91
Tumour targeting by microtubule-depolymerising vascular disrupting agents
Kanthou, C., & Tozer, G. M. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.11.1443 · Cited by 85
“Therefore, it is not surprising that during the last two decades, approaches that aim to target tumour blood vessels, in order to treat cancer, have taken centre stage [2,3] .”
BackgroundTodorova, M. I., Agache, V., Mortazavi, O., Chen, B., Karshafian, R., Hynynen, K., Man, S., Kerbel, R. S., & Goertz, D. E. (2012) · International Journal of Cancer · doi:10.1002/ijc.27977 · Cited by 80
“Majority of AA therapy has been conducted with AA agents (AAAs) that target specific aspects of the angiogenic cascade, such as monoclonal antibody inhibitors of VEGF-R2.(25) Low-dose continuous (or frequently applied) chemotherapy, referred to as metronomic chemotherapy, has also been widely investigated as a means o…”
BackgroundSelf-citationDoñate, F., Juárez, J., Burnett, M. E., Manuia, M., Guan, X., Shaw, D. E., Smith, E. L., Timuçin, A. C., Braunstein, M. J., Batuman, O., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604226 · Cited by 78
“Angiogenesis, the process of formation of new blood vessels from pre-existing ones, is critical for tumour growth and a promising therapeutic target for the treatment of cancer (Carmeliet, 2005; Doñate, 2005; Ferrara and Kerbel, 2005).”
BackgroundCharacterization and Regulation of Bv8 in Human Blood Cells
Zhong, C., Qu, X., Tan, M., Meng, Y. G., & Ferrara, N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1954 · Cited by 89
Self-citationRocha, L. A., Learmonth, D. A., Sousa, R. A., & Salgado, A. J. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.11.004 · Cited by 84
“In fact, several studies show that targeting tumor angiogenesis can stop the progression and metastasis of this disease (Ferrara and Kerbel, 2005).”
BackgroundTarnawski, A. S., Ahluwalia, A., & Jones, M. K. (2014) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12734 · Cited by 77
Bevacizumab: current updates in treatment
Meter, M. E. M. V., & Kim, E. S. (2010) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32833edc0c · Cited by 77
Portelli, M., & Baron, B. (2018) · Journal of Pregnancy · doi:10.1155/2018/2632637 · Cited by 96
“Through its interaction with its ligands, VEGFR-1 plays an important role in both physiologic and pathologic angiogenesis, the process by which new blood vessels are formed from preexisting vessels [43, 225, 226].”
BackgroundMa, J., & Waxman, D. J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0584 · Cited by 77
“Since the approval of bevacizumab for use in combination with 5-fluorouracil-based chemotherapy for metastatic colorectal cancer in 2004, several antiangiogenic drugs have been approved for cancer treatment and others are progressing through preclinical and clinical development (1, 2).”
BackgroundDesign and development of polymer conjugates as anti-angiogenic agents
Segal, E., & Satchi‐Fainaro, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.005 · Cited by 81
“bevacizumab [52], PTK787 [53] and SU6668 [54]) or by decreasing the vascular hyperpermeabilty through other mechanisms (e.”
BackgroundSelective Inhibition of Retinal Angiogenesis by Targeting PI3 Kinase
Álvarez, Y., Astudillo, O., Jensen, L. D., Reynolds, A., Waghorne, N., Brazil, D. P., Cao, Y., O'Connor, J. J., & Kennedy, B. N. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007867 · Cited by 79
Conconi, M. T., Marzaro, G., Urbani, L., Zanusso, I., Liddo, R. D., Castagliuolo, I., Brun, P., Tonus, F., Ferrarese, A., Guiotto, A., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.06.057 · Cited by 88
“Fibroblast Growth Factor (bFGF), Platelet Derived Growth Factor (PDGF), VEGF and EGF, are released thus inducing the angiogenesis process that in turn creates the basic conditions for cancer growth and metastasis [26,27].”
BackgroundQuesada, A. R., Medina, M. Á., & Alba, E. (2007) · BioEssays · doi:10.1002/bies.20655 · Cited by 82
Palmowski, M., Huppert, J., Hauff, P., Reinhardt, M., Schreiner, K., Socher, M. A., Hallscheidt, P. J., Kauffmann, G. W., Semmler, W., & Kiessling, F. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0285 · Cited by 77
“A crucial issue for emerging approaches of antiangiogenic therapy is the ability to directly quantify their effects longitudinally in the tumor neovasculature (2).”
BackgroundActive Immunotherapy Induces Antibody Responses That Target Tumor Angiogenesis
Schoenfeld, J., Jinushi, M., Nakazaki, Y., Wiener, D., Park, J., Soiffer, R., Neuberg, D., Mihm, M., Hodi, F. S., & Dranoff, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1852 · Cited by 77
Evidence for Pro-angiogenic Functions of VEGF-Ax
Xin, H., Zhong, C., Nudleman, E., & Ferrara, N. (2016) · Cell · doi:10.1016/j.cell.2016.08.054 · Cited by 87
“Several families of mediators of angiogenesis have been described (Carmeliet and Jain, 2011; Kerbel, 2008), but it is nowwell established that VEGF-A is an essential regulator of this process (Ferrara and Kerbel, 2005).”
BackgroundSelf-citationUnique biology of gliomas: challenges and opportunities
Watkins, S., & Sontheimer, H. W. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.05.001 · Cited by 86
Cesca, M., Bizzaro, F., Zucchetti, M., & Giavazzi, R. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00259 · Cited by 75
Ding, W. J., Nothaft, H., Szymanski, C. M., & Kelly, J. F. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900088-mcp200 · Cited by 79
Insulin-like Growth Factor 1 (IGF-1) Stabilizes Nascent Blood Vessels
Jacobo, S. M. P., & Kazlauskas, A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.634154 · Cited by 80
Targeted therapy of thyroid cancer
Sherman, S. I. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.05.003 · Cited by 77
Nanotheranostics Targeting the Tumor Microenvironment
Roma‐Rodrigues, C., Pombo, I., Raposo, L. R., Pedrosa, P., Fernandes, A. R., & Baptista, P. V. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00197 · Cited by 84
Fu, S., He, S.-Y., Xu, B., Hu, C., Lu, S.-F., Shen, W., Huang, Y., Hong, H., Li, Q., Wang, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094604 · Cited by 75
The use of bevacizumab in non-small cell lung cancer: an update.
Lauro, S. D., Onesti, C. E., Righini, R., & Marchetti, P. (2014) · PubMed · Cited by 75
Ursolic acid-loaded chitosan nanoparticles induce potent anti-angiogenesis in tumor
Jin, H., Pi, J., Yang, F., Wu, C., Cheng, X., Bai, H., Huang, D., Jiang, J., Cai, J., & Chen, Z. W. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7360-8 · Cited by 76
“Studies showed that growing tumors could become inactive if they cannot find a new supply of nutrients; thus, antiangiogenesis has become one of the important strategies for many types of cancer therapies (Carmeliet and Jain 2011; Ferrara and Kerbel 2005; del Puerto-Nevado et al. 2014).”
BackgroundDual targeting of ANGPT1 and TGFBR2 genes by miR-204 controls angiogenesis in breast cancer
Flores‐Pérez, A., Marchat, L. A., Rodriguez-Cuevas, S. A., Bautista‐Piña, V., Hidalgo‐Miranda, A., Aréchaga-Ocampo, E., Martínez, M. S., Flores, C. P., Fonseca-Sánchez, M. A., la Vega, H. A., et al. (2016) · Scientific Reports · doi:10.1038/srep34504 · Cited by 80
Angiotensinogen Delays Angiogenesis and Tumor Growth of Hepatocarcinoma in Transgenic Mice
Vincent, F., Bonnin, P., Clemessy, M., Contrerès, J.-O., Lamandé, N., Gasc, J., Vilar, J., Hainaud, P., Tobelem, G., Corvol, P. L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2484 · Cited by 77
“Numerous molecules have been reported to be involved in this process and blocking angiogenesis has given promising results in cancer therapies (1, 2).”
BackgroundKim, B., Cho, H., Chung, J., Conway, C. M., Ylaya, K., Kim, J., & Hewitt, S. M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-185 · Cited by 77
“Increased HIF-1α activates target genes involved in tumor cell growth, angiogenesis, metabolism, apoptosis and metastasis [4,9].”
BackgroundAn aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells
Ara, M. N., Matsuda, T., Hyodo, M., Sakurai, Y., Hatakeyama, H., Ohga, N., Hida, K., & Harashima, H. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.04.087 · Cited by 79
Karathanasis, E., Chan, L., Karumbaiah, L., McNeeley, K., D'Orsi, C. J., Annapragada, A. V., Sechopoulos, I., & Bellamkonda, R. V. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005843 · Cited by 74
Natsuizaka, M., Ozasa, M., Darmanin, S., Miyamoto, M., Kondo, S., Kamada, S., Shindoh, M., Higashino, F., Suhara, W., Koide, H., et al. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.06.013 · Cited by 81
“[7] N.”
BackgroundSaraswati, S., & Agrawal, S. S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.012 · Cited by 75
Kumar, S., Sharghi-Namini, S., Rao, N., & Ge, R. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.05.022 · Cited by 79
Building better magic bullets — improving unconjugated monoclonal antibody therapy for cancer
Weiner, L. M. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2209 · Cited by 82
“The concept of monoclonal antibody binding to the ligand to prevent its interaction with a cell surface receptor has been used in the case of vascular endothelial growth factor ( VEGF”
MethodTherapeutic options to target angiogenesis in human malignancies
Herbst, R. S. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.4.635 · Cited by 76
“VEGFA is the most abundantly expressed angiogenic growth factor in solid and haematological malignancies [7,8].”
BackgroundRole of hydrogen sulphide in physiological and pathological angiogenesis
Zhang, Y., Jing, M., Cai, C., Zhu, S., Zhang, C.-J., Wang, Q., Zhai, Y., Ji, X., & Wu, D. (2022) · Cell Proliferation · doi:10.1111/cpr.13374 · Cited by 79
“As a therapeutic target, angiogenesis plays an irreplaceable role in the recovery of ischaemic diseases.(6,111) NaHS can promote the”
BackgroundOkazaki, T., Ebihara, S., Asada, M., Yamanda, S., Niu, K., & Arai, H. (2008) · Neoplasia · doi:10.1593/neo.08140 · Cited by 73
“However, recent studies in mice suggest that hematopoietic growth factors such as macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) can cause tumor growth by promoting angiogenesis [1] [2] [3], which supplies blood to solid tumors [4] [5].”
BackgroundDynamic contrast enhanced ultrasound for therapy monitoring
Hudson, J. M., Williams, R., Tremblay‐Darveau, C., Sheeran, P. S., Milot, L. M., Bjarnason, G. A., & Burns, P. N. (2015) · European Journal of Radiology · doi:10.1016/j.ejrad.2015.05.013 · Cited by 73
“Over the past 10–15 years, targeting of the vascular endothelial growth factor (VEGF) pathway has shown clinical benefit in patients with metastatic colorectal cancer, advanced non small cell lung cancer, hepatocellular carcinoma, metastatic breast cancer and renal cell carcinoma [39].”
Pang, X., Wu, Y., Wu, Y., Lu, B., Chen, J., Wang, J., Yi, Z., Qu, W., & Liu, M. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0936 · Cited by 74
“Solid tumors recruit new blood vessels for their growth, maintenance, and metastasis (1, 2).”
BackgroundBenedito, R., Trindade, A., Hirashima, M., Henrique, D., Lopes-da-Costa, L., Rossant, J., Gill, P. S., & Duarte, A. (2008) · BMC Developmental Biology · doi:10.1186/1471-213x-8-117 · Cited by 83
“The Dll4-/- arterial endothelial cells express more VEGFR-2 which is required for VEGF mediated endothelial cell migration and proliferation [40].”
BackgroundPathogenesis of infantile haemangioma: new molecular and cellular insights
Ritter, M. R., Butschek, R. A., Friedlander, M., & Friedlander, S. F. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940700052x · Cited by 74
Caporarello, N., Lupo, G., Olivieri, M., Cristaldi, M., Cambria, M. T., Salmeri, M., & Anfuso, C. D. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7179 · Cited by 84
“VEGFR3 is mostly involved in lymphangiogenesis and has a minor role in vascular angiogenesis (9).”
In vitro antiproliferative and antiangiogenic effects of synthetic chalcone analogues
Pilátová, M. B., Varinská, L., Perjési, P., Šarišský, M., Mirossay, L., Solár, P., Ostro, A., & Mojžíš, J. (2010) · Toxicology in Vitro · doi:10.1016/j.tiv.2010.04.013 · Cited by 72
“Thus, suppression of abnormal angiogenesis may provide therapeutic strategies in the treatment of cancer disease (Ferrara and Kerbel, 2005).”
BackgroundVEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A
Catena, R., Larzábal, L., Larráyoz, M., Molina, E., Hermida, J., Agorreta, J., Montes, R., Pío, R., Montuenga, L. M., & Calvo, A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-320 · Cited by 92
“They showed VEGF165b to be a weak agonist of VEGFR2 and to induce its phosphorylation in HUVECs with a similar potency as VEGF145.”
BackgroundInfluentialDeMorrow, S., Francis, H., Gaudio, E., Venter, J., Franchitto, A., Kopriva, S., Onori, P., Mancinelli, R., Frampton, G., Coufal, M., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90455.2008 · Cited by 72
“These factors are necessary for the vascularization of the tumors (13, 14) and contribute to the development and growth of cholangiocarcinoma tumors.”
BackgroundTarget-based therapies in breast cancer: current status and future perspectives
Normanno, N., Morabito, A., Luca, A. D., Piccirillo, M. C., Gallo, M., Maiello, M. R., & Perrone, F. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0208 · Cited by 94
“…regulation of tumor-associated neoangiogenesis is VEGF-A (from now referred as VEGF), although additional growth factors, such as interleukin-8, basic fibroblast growth factor and the EGFR ligands EGF and TGF-a, might play a role in this phenomenon (Ferrara & Kerbel 2005, Kowanetz & Ferrara 2006).”
BackgroundAnti-Dll4 therapy: can we block tumour growth by increasing angiogenesis?
Sainson, R. C. A., & Harris, A. L. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.002 · Cited by 81
Siemann, D. W., Chaplin, D. J., & Horsman, M. R. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1364745 · Cited by 78
“Most AAs target the angiogenic factors secreted by tumor cells (14) and suppress tumor growth by inhibiting the migration and proliferation of endothelial cells (15, 16).”
BackgroundAbdallah, A. E., Eissa, S. I., Ward, M. M. S. A., Mabrouk, R. R., Mehany, A. B. M., & El‐Zahabi, M. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104695 · Cited by 71
Insights into the glioblastoma tumor microenvironment: current and emerging therapeutic approaches
Tripathy, D. K., Panda, L. P., Biswal, S., & Barhwal, K. K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1355242 · Cited by 84
“Understanding the fi brocytes that promote tumor growth improves our understanding of GBM and opens the door to more intelligent treatment approaches.”
BackgroundInfluentialHan, M. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1138 · Cited by 72
Phung, T. L., Oble, D. A., Jia, W., Benjamin, L. E., Mihm, M. C., & Nelson, J. S. (2008) · Lasers in Surgery and Medicine · doi:10.1002/lsm.20599 · Cited by 71
Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature
Hedlund, E., Hosaka, K., Zhong, Z., Cao, R., & Cao, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908026106 · Cited by 78
Redente, E. F., Orlicky, D. J., Bouchard, R. J., & Malkinson, A. M. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.060566 · Cited by 71
“Recent therapeutic strategies combine cytotoxic agents acting directly on proliferating tumor cells with anti-angiogenic or anti-inflammatory drugs that target supportive cells.(7) Cisplatin”
BackgroundBhide, R. S., Lombardo, L. J., Hunt, J. T., Cai, Z., Barrish, J. C., Galbraith, S. M., Jeyaseelan, R., Mortillo, S., Wautlet, B. S., Krishnan, B. S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0472 · Cited by 73
“Mol Cancer Ther; 9(2) February 2010 tion of 11.”
BackgroundMethodResultInfluentialSekiguchi, K., Ito, Y., Hattori, K., Inoue, T., Hosono, K., Honda, M., Numao, A., Amano, H., Shibuya, M., Unno, N., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43185-8 · Cited by 75
Therapeutic Targets of Multiple Angiogenic Factors for the Treatment of Cancer and Metastasis
Cao, Y., & Liu, Q. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97009-2 · Cited by 76
Angiogenesis and ovarian cancer
Gómez-Raposo, C., Mendiola, M., Barriuso, J., Casado, E., Hardisson, D., & Redondo, A. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0406-y · Cited by 70
Therapeutic potential of interfering with apelin signalling
Sorli, S., Berghe, L. V. D., Masri, B., Knibiehler, B., & Audigier, Y. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.011 · Cited by 72
Fountzilas, G., Fragkoulidi, A., Kalogera‐Fountzila, A., Nikolaidou, M., Bobos, M., Caldéraro, J., Andreiuolo, F. D. M., & Μαρσέλος, Μ. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1070-1 · Cited by 70
Heparan sulfate in angiogenesis: a target for therapy
van Wijk, X. M. R., & Kuppevelt, T. H. V. (2013) · Angiogenesis · doi:10.1007/s10456-013-9401-6 · Cited by 85
“thrombospondin 1 (TSP1), platelet factor 4 (PF4) and endostatin [1–3].”
Background
Metadata
- Authors
- Ferrara, N., & Kerbel, R. S.
- Affiliations
- Genentech (US)
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature
- Published
- 2005-12
- Volume
- 438
- Issue
- 7070
- Pages
- 967-974
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2084740377
- Semantic Scholar
- 19591ab68a155b2d341266c48a9ef957bd4ba612
- Cited by
- 2,653
- References
- 102
- Citations by year
- 2026: 39 · 2025: 57 · 2024: 72 · 2023: 69 · 2022: 75 · 2021: 102 · 2020: 114 · 2019: 95 · 2018: 97 · 2017: 124 · 2016: 160 · 2015: 164 · 2014: 158 · 2013: 171 · 2012: 164
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- angiogenesis, anti-angiogenic therapy, therapeutic angiogenesis, cancer therapy, age-related macular degeneration, antiangiogenic drugs, vascular morphogenesis
- MeSH terms
- Animals, Bone Marrow Cells, Clinical Trials as Topic, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Drug Resistance, Neoplasm, Angiogenesis Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.